Business Overview: HCW Biologics Inc. (NASDAQ: HCWB)

---

Executive Summary

HCW Biologics Inc. is a clinical-stage biopharmaceutical company headquartered in Miramar, Florida, founded by immunologist Dr. Hing C. Wong. It develops fusion-protein immunotherapeutics aimed at chronic inflammation, autoimmune disease, cancer, and senescence-associated conditions, built on two proprietary protein-engineering platforms the company says have produced over 50 distinct molecules.

HCW Biologics matters less for commercial scale — it has no approved drugs and reported a going-concern doubt as recently as its Q1 2025 financial results — than as a case study in how a small, platform-driven biotech tries to survive the long, expensive road to approval: by out-licensing pipeline assets for non-dilutive cash, selling GMP-grade research reagents to cell-therapy manufacturers, and dosing its lead clinical candidate while continuously raising capital just to keep the lights on.

---

1. Core Business Model & How They Work

HCW Biologics pursues a three-pronged model layered on top of a core R&D engine, designed to generate near-term cash while its own clinical pipeline matures.

   Proprietary Platforms (TOBI, TRBC scaffolds)
                    │
                    ▼
      ┌─────────────────────────────┐
      │   50+ Fusion-Protein         │
      │   Molecules Created          │
      └─────────────────────────────┘
          │            │            │
          ▼            ▼            ▼
   Company-Sponsored  Out-Licensing   Reagent Sales
   Clinical Trials     to Partners    (HCW9206,
   (e.g., HCW9302      (Wugen,         HCW9201) to
   in alopecia         Trimmune)       CAR-T / NK
   areata)                             cell-therapy
          │            │              manufacturers
          ▼            ▼                    │
     Potential Drug   Upfront Fees,          ▼
     Approval /        Milestones,     Recurring,
     Royalties         Equity Stakes   Non-Dilutive
     (long-term)       (near-term      Revenue
                        cash)          (near-term)

➡️ The reagent and out-licensing businesses exist primarily to fund the clinical pipeline without excessive share dilution — a necessity given the company's thin cash position.

---

2. Business Segments

HCW Biologics does not report discrete financial segments; the business is best understood as three activity lines built on common underlying science:

                     HCW Biologics Inc.
                            │
   ┌────────────────────────┼────────────────────────┐
   ▼                        ▼                         ▼
Clinical Pipeline      Out-Licensing &           Reagent Sales
(HCW9302 lead;         Partnerships              (HCW9206, HCW9201
HCW11-018b,            (Wugen license;           for CAR-T/NK cell
HCW11-040,             Trimmune option on         manufacturing;
HCW11-006 preclinical) HCW11-006 China rights)    GMP cell banks,
                                                    FDA Drug Master Files)

• Clinical Pipeline: Lead candidate HCW9302, an IL-2 fusion protein designed to expand regulatory T cells, entered Phase 1 testing in alopecia areata, with the first patient dosed in November 2025. Preclinical assets HCW11-018b (a tetravalent T-cell engager for solid tumors) and HCW11-040 (a cytokine/pembrolizumab fusion molecule targeting bronchopulmonary dysplasia) are expected to complete IND-enabling studies in 2027.
• Out-Licensing & Partnerships: Wugen has generated $16.2 million in cumulative license revenue since inception (though an associated R&D reimbursement is currently suspended). Trimmune holds exclusive worldwide in vivo rights to HCW11-006 and an option on Chinese rights to HCW9302, with HCW Biologics retaining an Americas opt-in after Trimmune's China Phase 1 — plus HCW Biologics received a $3.5 million upfront fee and a minority equity stake in Trimmune.
• Reagent Sales: HCW9206 and HCW9201 are sold as commercial-ready reagents to manufacturers of CAR-T and NK cell therapies, backed by GMP cell banks and Drug Master Files filed with the FDA — a lower-risk, recurring-revenue complement to the clinical business.

---

3. Product Portfolio

---

4. Competitive Landscape

HCW Biologics competes across several distinct therapeutic and technology niches rather than one market:

• Oncology / T-cell engagers: large, well-capitalized players including AbbVie, Amgen, Bristol Myers Squibb, Merck, and Pfizer, alongside other dedicated T-cell-engager and CAR-T developers.
• Regulatory T-cell / IL-2 biology: Amgen, Coya Therapeutics, Nektar, and Genentech, among others working on engineered IL-2 and Treg-expansion approaches.
• Senescence and aging biology: well-funded specialists Altos Labs, Calico, Rubedo Life Sciences, and Unity Biotechnology.
• Checkpoint inhibitor-adjacent approaches: dominated by Merck's Keytruda (pembrolizumab), the molecule HCW11-040 is itself designed to pair with.

                High Capital Intensity / Scale
                        │
    AbbVie, Amgen, BMS, │
    Merck, Pfizer       │
          ●              │
                        │
  ───────────────────────┼───────────────────────
  Broad Pipeline         │          Narrow, Platform-
  (many modalities)      │          Focused Pipeline
                        │
      Altos Labs ●       │   ● HCW Biologics
      Coya, Nektar ●     │     (TOBI/TRBC scaffolds,
                        │      licensing + reagents)
                Low Capital Intensity / Scale

HCW Biologics sits in the low-capital, platform-focused quadrant — a position that lets it move fast and monetize partial assets via licensing and reagents, but leaves it structurally dependent on outside capital and partners to reach any single program's finish line.

---

5. Strategic Strengths & Risks

Strengths

• Two proprietary scaffold platforms (TOBI and TRBC) have generated a genuinely broad library of over 50 fusion-protein molecules, giving the company more shots on goal than a typical single-asset biotech.
• A diversified, partially non-dilutive funding model: the Wugen license alone has generated $16.2 million cumulatively, and the Trimmune deal added a $3.5 million upfront fee plus equity.
• A reagent business (HCW9206/HCW9201) with FDA Drug Master Files creates real switching costs once a cell-therapy manufacturer has validated and filed around those specific reagents.

Risks

• Going concern doubt: the company explicitly disclosed substantial doubt about its ability to continue as a going concern as of Q1 2025, with cash falling to roughly $1.1 million by March 31, 2025, before a May 2025 equity raise and note conversion provided a bridge.
• No approved products: every near-term value driver — HCW9302's Phase 1 readout, further out-licensing deals, or reagent adoption — remains unproven at commercial scale.
• Partner dependence: material value (Wugen reimbursements, Trimmune milestones, China rights economics) depends on counterparties' own decisions and funding, not HCW Biologics' control.
• Intensely competitive, well-funded rivals in every therapeutic area it touches, from large pharma in oncology to richly-funded pure-play senescence biotechs.

---

6. Financial Overview

---

Summary Conclusion

HCW Biologics' real asset is its underlying protein-engineering science — two platforms that have already produced a lead clinical candidate, two licensing partnerships, and a recurring reagent business, which together give it more diversified shots at value creation than many single-asset biotechs. But none of that offsets the fundamental risk facing the company: it has explicitly disclosed going-concern doubt, its cash runway depends on a steady cadence of dilutive financings and partner milestones it cannot fully control, and every one of its therapeutic areas is contested by far larger, better-capitalized competitors. The business case ultimately rests on whether HCW9302's Phase 1 data and continued reagent/licensing cash flow arrive fast enough to outrun its own capital constraints.